Skip to main content
main-content

Breast cancer

News and opinion

21-10-2018 | Triple-negative breast cancer | ESMO 2018 | News

IMpassion130 supports atezolizumab use in triple-negative breast cancer

Results for the IMpassion130 trial support the combination of atezolizumab and nab-paclitaxel for the treatment of metastatic triple-negative breast cancer, especially among patients with programmed cell death ligand 1-positive disease.

21-10-2018 | Breast cancer | ESMO 2018 | News

Adding alpelisib to fulvestrant boosts PI3KCA-mutant metastatic breast cancer PFS

Patients with hormone receptor-positive, HER2-negative metastatic breast cancer harboring PI3KCA mutations derive a significant progression-free survival benefit when fulvestrant is supplemented with the PI3K inhibitor alpelisib, phase III data show.

20-10-2018 | Breast cancer | ESMO 2018 | News

Further evidence for palbociclib addition in advanced breast cancer

PALOMA-3 trial findings show that overall survival is significantly improved with the addition of the CDK4/6 inhibitor palbociclib to fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer and sensitivity to prior endocrine therapy.

12-10-2018 | Breast cancer | News

Endocrine therapy impacts cardiovascular risk in women with breast cancer

Long-term use of adjuvant endocrine therapy by women with a history of nonmetastatic breast cancer can significantly alter their risk for some types of cardiovascular disease, a meta-analysis shows.

11-10-2018 | Breast cancer | News

Postmenopausal weight loss linked to reduced breast cancer risk

Postmenopausal women who lose weight have a lower risk for breast cancer than those who maintain a stable weight, report researchers.

10-10-2018 | Chemotherapy | News

Short-term hospitalization, mortality risk varies by palliative chemotherapy regimen

Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.

09-10-2018 | Breast cancer | News

Lurbinectedin activity shown in metastatic breast cancer

Lurbinectedin, a selective inhibitor of active transcription of protein-coding genes, has promising activity in patients with BRCA1/2-mutated metastatic breast cancer, phase II study data show.

18-09-2018 | EMA | News

Durvalumab, abemaciclib approvals announced by EMA

Click through to read more

03-09-2018 | Advanced breast cancer | News

EMBRACA results demonstrate talazoparib advanced breast cancer benefits

The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1/2 mutation.

31-08-2018 | Breast cancer | News

In other news: Breast cancer treatment effects

The focus this month is on early and late treatment effects in patients with breast cancer, including effects on endometrial cancer risk, cardiotoxicity, and skin toxicity.

28-08-2018 | HER2-positive breast cancer | News

Adding pertuzumab to trastuzumab effective for HER2-positive breast cancer

Adding pertuzumab to trastuzumab plus an aromatase inhibitor may be effective for patients with human HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer, a phase II trial suggests.

23-08-2018 | Targeted therapy | News

New molecular target classification system could aid treatment decision making

The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.

20-08-2018 | Ductal carcinoma in situ | News

Adjuvant radiotherapy may improve DCIS outcomes

Canadian researchers have found that the use of radiotherapy after surgery for ductal carcinoma in situ leads to an improvement in breast cancer-specific survival, possibly due to its systemic effects.

10-08-2018 | Bevacizumab | News

Adjuvant bevacizumab not recommended for melanoma, HER2-negative breast cancer

The AVAST-M and E5103 trial results rule out the use of bevacizumab in the adjuvant setting in high-risk patients with cutaneous melanoma and HER2-negative breast cancer, respectively.

07-08-2018 | Hormone-receptor positive breast cancer | News

CTCs may predict risk for late breast cancer recurrence

Women with detectable circulating tumor cells at least 5 years after diagnosis of hormone receptor-positive breast cancer have a substantially increased risk for late clinical recurrence, clinical trial data show.

02-08-2018 | Breast cancer | Editorial | Article

Developing polygenic risk scores for breast cancer

Gareth Evans (University of Manchester, UK) details how genetic advances have allowed the development of relatively cheap and clinically meaningful genetic-based scores for breast cancer risk, further heralding the shift towards precision medicine in breast cancer.

01-08-2018 | FDA | News

Magnetic device helps guide breast cancer SLN biopsy

More on this US FDA decision here

30-07-2018 | Breast cancer | News

TGFB1 gene key determinant of breast fibrosis risk

Carriers of the C−509T allele in the transforming growth factor ß 1 gene have a significantly increased risk for late breast fibrosis following breast-conserving surgery and whole-breast irradiation for stage 0 to IIA breast cancer, researchers report.

26-07-2018 | FDA | News

Ribociclib indication expanded to pre-, perimenopausal patients

Read more about this FDA update here

26-07-2018 | Complementary and alternative medicine | News

Complementary medicine use linked to conventional cancer care refusal

Cancer patients who use complementary medicine are more likely to refuse conventional care than nonusers, suggests a study that uncovered a link between this pattern and poor survival.

Image Credits